Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMTGNWU)

Drug Name
Tofisopam Drug Info
Synonyms
tofisopam; 22345-47-7; Grandaxin; Seriel; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; Egyt 341; Tofisopamum; 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-; tofizopam; NCGC00165912-02; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine; benzodiazepine; EGYT 341; Grandaxin; Nodeprine; Seriel; Tofisopamum [INN-Latin]; 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine; Tofisopam [INN:DCF:JAN]; EINECS 244-922-3; CCRIS 8738; Emandaxin (TN); DSSTox_CID_3681; Tofisopam (JP17/INN); DSSTox_RID_77145; DSSTox_GSID_23681; SCHEMBL43522; Tofisopam (patented in japan); CHEMBL404216; SCHEMBL8086894; DTXSID3023681; CHEBI:32241; BCP09600; Tox21_112269; MFCD00823171; Tofisopam, >=98% (HPLC), solid; AKOS025401672; DB08811; QC-1212; NCGC00165912-01; NCGC00165912-03; AC-24288; LS-14948; CAS-22345-47-7; DB-045872; FT-0638212; X6663; D01254; 345T477; Q945537; Q-201839; BRD-A69095630-001-01-1; 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine; 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine; (1Z,3Z)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine
Indication
Disease Entry ICD 11 Status REF
Hyperuricaemia 5C55.Y Phase 2 [1]
Irritable bowel syndrome DD91.0 Phase 2 [2]
Cross-matching ID
PubChem CID
5502
ChEBI ID
CHEBI:32241
CAS Number
CAS 22345-47-7
TTD Drug ID
DMTGNWU

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 10A (PDE10) TTJW4LU PDE10_HUMAN Inhibitor [3]
Phosphodiesterase 2A (PDE2A) TTJGW1Z PDE2A_HUMAN Inhibitor [3]
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Inhibitor [3]
Phosphodiesterase 4A (PDE4A) TTZ97H5 PDE4A_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Phosphodiesterase 4A (PDE4A) DTT PDE4A 4.1 2.787 2.379 3.433
Phosphodiesterase 10A (PDE10) DTT PDE10A 5.313 4.436 5.65 5.516
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hyperuricaemia
ICD Disease Classification 5C55.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 4A (PDE4A) DTT PDE4A 9.26E-01 -3.01E-03 -0.01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01519687) Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00486876) A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome. U.S. National Institutes of Health.
3 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.